Effect of CYP2C9 and VKORC1 genetic variations on warfarin dose requirements in Indian patients

Background: warfarin,an oral anticoagulant is used in patients who are at increased risk of developing blood clots. the management of warfarin therapy is challenging because it shows large inter and intra individual variability in patient response due to factors like age,gender,diet,concurrent drug interactions and variations in cyp2c9 and vkorc1 genes. studies implicate that polymorphisms in vkorc1 and cyp2c9 genes are associated with reduced doses of warfarin. the aim of our current study was to characterize the effects of vkorc1 and cyp2c9 gene variations that contribute to variability in warfarin dosing in indian patients. methods: genomic dna was extracted from 103 patients undergoing warfarin therapy. their mean daily warfarin dose,inr and demographics were recorded and genotyping of vkorc1 and cyp2c9 gene was performed by pcr-rflp method. results: individuals with wild type genotypes required highest mean warfarin dosage of 4.72 mg/day while vkorc1 variants required 3.6 mg/day to maintain their therapeutic inr. cyp2c92 genotype was not found to affect the warfarin maintenance dosages. the odds ratio for developing supra therapeutic inr in patients carrying vkorc1 variant allele when compared to wild types was 13.96 (95% ci; 4.85-44.65. other factors affecting warfarin dosages were age and weight. conclusion: inclusion of pharmacogenetic data along with clinical parameters would help better predict warfarin doses in indian patients. copyright © 2013 by institute of pharmacology polish academy of sciences.